IRMD (iRadimed) Cyclically Adjusted Revenue per Share: $4.57 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRMD iRadimed Corp IRMD
92 GF Score
Price $87.55
GF Value $65.80
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is iRadimed Cyclically Adjusted Revenue per Share?

iRadimed IRMD -0.08% 92 Cyclically Adjusted Revenue per Share is $4.57 as of Jun. 2026. GuruFocus rates IRMD with a GF Score™ of 92/100 and a GF Value™ of $65.80 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

iRadimed's adjusted revenue per share for the three months ended in Jun. 2026 was $1.590. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.57 for the trailing ten years ended in Jun. 2026.

During the past 12 months, iRadimed's average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of iRadimed was 13.60% per year. The lowest was 13.60% per year. And the median was 13.60% per year.

As of today (2026-08-19), iRadimed's current stock price is $87.55. iRadimed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $4.57. iRadimed's Cyclically Adjusted PS Ratio of today is 19.16.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of iRadimed was 23.97. The lowest was 9.55. And the median was 13.74.


iRadimed  (NAS:IRMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

iRadimed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=87.55/4.57
=19.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of iRadimed was 23.97. The lowest was 9.55. And the median was 13.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


iRadimed Cyclically Adjusted Revenue per Share Related Terms


iRadimed Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for iRadimed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iRadimed Cyclically Adjusted Revenue per Share Chart

iRadimed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.95 3.43 3.91 4.32

iRadimed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.14 4.25 4.32 4.47 4.57

IRMD vs AORT, TNDM, AVNS: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, iRadimed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRadimed Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where iRadimed's Cyclically Adjusted PS Ratio falls into.


IRMD
92GF Score
iRadimed Corp IRMD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iRadimed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, iRadimed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.59/333.9520*333.9520
=1.590

Current CPI (Jun. 2026) = 333.9520.

iRadimed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.647 241.428 0.895
201612 0.508 241.432 0.703
201703 0.481 243.801 0.659
201706 0.471 244.955 0.642
201709 0.489 246.819 0.662
201712 0.571 246.524 0.774
201803 0.598 249.554 0.800
201806 0.614 251.989 0.814
201809 0.624 252.439 0.825
201812 0.680 251.233 0.904
201903 0.690 254.202 0.906
201906 0.755 256.143 0.984
201909 0.809 256.759 1.052
201912 0.881 256.974 1.145
202003 0.702 258.115 0.908
202006 0.563 257.797 0.729
202009 0.616 260.280 0.790
202012 0.683 260.474 0.876
202103 0.737 264.877 0.929
202106 0.781 271.696 0.960
202109 0.865 274.310 1.053
202112 0.939 278.802 1.125
202203 0.973 287.504 1.130
202206 1.007 296.311 1.135
202209 1.061 296.808 1.194
202212 1.177 296.797 1.324
202303 1.220 301.836 1.350
202306 1.268 305.109 1.388
202309 1.296 307.789 1.406
202312 1.370 306.746 1.492
202403 1.380 312.332 1.476
202406 1.405 314.175 1.493
202409 1.434 315.301 1.519
202412 1.509 315.605 1.597
202503 1.521 319.799 1.588
202506 1.590 322.561 1.646
202509 1.649 324.800 1.695
202512 1.760 324.054 1.814
202603 1.708 330.213 1.727
202606 1.590 333.952 1.590

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.57 mean?
iRadimed (IRMD) has a Cyclically Adjusted Revenue per Share of $4.57 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on iRadimed and its competitors.
Is iRadimed's Cyclically Adjusted Revenue per Share too high?
iRadimed's current Cyclically Adjusted Revenue per Share is $4.57. Overall, iRadimed has a GF Score™ of 92/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Cyclically Adjusted Revenue per Share compare to AORT and TNDM?
iRadimed's Cyclically Adjusted Revenue per Share of $4.57 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on iRadimed and its competitors. iRadimed's current Cyclically Adjusted Revenue per Share is $4.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (IRMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $65.80, compared to a current price of $87.55 — trading 33.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.57. iRadimed's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For iRadimed (IRMD), the current Cyclically Adjusted Revenue per Share is $4.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iRadimed (IRMD) Overvalued in 2026?

Based on GuruFocus' analysis, iRadimed stock appears to be overvalued. The current stock price of $87.55 is trading 33.1% above its estimated GF Value™ of $65.80. GuruFocus considers iRadimed to be Significantly Overvalued.

Key valuation signals for IRMD:

  • Cyclically Adjusted Revenue per Share: $4.57
  • GF Value™: $65.80 vs. price of $87.55 (33.1% above fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the IRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iRadimed Business Description

Other Exchanges 46K:Germany
Address 12705 Ingenuity Drive, Orlando, FL, USA, 32826
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
92GF Score

Get the complete analysis for IRMD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.55
Price
$65.80
GF Value